Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis

(2011) Russell A. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group

(2009) Naureen Starling et al.   JOURNAL OF CLINICAL ONCOLOGY

Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents

(2009) Maurizio Zangari et al.   JOURNAL OF CLINICAL ONCOLOGY

A step in the right direction, but one size might not fit all

(2009) Simon Noble   LANCET ONCOLOGY

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

(2009) Giancarlo Agnelli et al.   LANCET ONCOLOGY

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD

Prevention of Venous Thromboembolism

(2008) William H. Geerts et al.   CHEST

Gemcitabine: vascular toxicity and prothrombotic potential

(2008) Constantin A Dasanu   Expert Opinion On Drug Safety

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

(2008) Salah-Eddin Al-Batran et al.   JOURNAL OF CLINICAL ONCOLOGY